PhaseBio Pharmaceuticals, Inc. PHASQ OTC

PhaseBio Pharmaceuticals, Inc. (PHASQ) has shown exceptional revenue growth over the past 3 years, expanding from $668,000 to $10,831 (average +23.5%/yr). The company reported a net loss of $131,071 in its most recent fiscal year, with earnings trending at -38.6%/yr. The net profit margin is -1210.1%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 100% (high), with a +0pp trend over the period. With a market cap data available and MOAT composite score of 46/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (58/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 6-year history, the company was profitable in 0 of 6 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (46/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 31/100 with 0/6 criteria passed.